Bronchiectasis - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026

Bronchiectasis Emerging Therapy and TPP Insights

Thelansis's "Bronchiectasis Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Bronchiectasis Overview

Bronchiectasis is a chronic, progressive structural lung disease characterised by irreversible pathological dilatation and destruction of the bronchial walls - resulting from a self-perpetuating cycle of recurrent infection, neutrophilic airway inflammation, and impaired mucociliary clearance - producing permanently damaged, mucus-laden airways susceptible to chronic bacterial colonisation. Underlying aetiologies are diverse, encompassing post-infectious damage, cystic fibrosis, primary ciliary dyskinesia, immunodeficiency states, allergic bronchopulmonary aspergillosis, connective tissue disorders, and inflammatory bowel disease-associated airway disease, with a significant proportion remaining idiopathic despite thorough investigation. Patients present with chronic productive cough, mucopurulent sputum, recurrent pulmonary exacerbations, dyspnoea, and haemoptysis; high-resolution CT demonstrating airway dilatation exceeding accompanying vessel diameter - the signet ring sign - alongside bronchial wall thickening and tree-in-bud opacification establishes diagnosis. Sputum microbiology - identifying Pseudomonas aeruginosa, Haemophilus influenzae, and non-tuberculous mycobacteria - guides antimicrobial selection. Airway clearance physiotherapy and mucoactive agents - hypertonic saline and nebulised mannitol - remain therapeutic cornerstones alongside targeted treatment of underlying aetiology. Inhaled tobramycin or azithromycin-based long-term antibiotic strategies reduce exacerbation frequency in Pseudomonas-colonised patients. Bronchoscopic or surgical intervention addresses localised disease or refractory haemoptysis. Prognosis varies with aetiology and exacerbation burden; multidisciplinary management, regular microbiological surveillance, pulmonary rehabilitation, and patient-centred self-management education are integral to optimising long-term respiratory outcomes.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• GlaxoSmithKline
• AstraZeneca
• CSL Behring
• S-INFINITY Pharmaceuticals Co., Ltd
• Shanghai Huilun Pharmaceutical Co., Ltd.
• Boehringer Ingelheim
• Haisco Pharmaceutical Group Co., Ltd.
• Thirty Respiratory Limited
• Genentech, Inc.
• Verona Pharma plc
• Sanofi
• Chiesi Farmaceutici S.p.A.
• Armata Pharmaceuticals, Inc.
• Renovion, Inc.
• Insmed Incorporated
• Reistone Biopharma Company Limited